[go: up one dir, main page]

SE9803959D0 - inhibitors - Google Patents

inhibitors

Info

Publication number
SE9803959D0
SE9803959D0 SE9803959A SE9803959A SE9803959D0 SE 9803959 D0 SE9803959 D0 SE 9803959D0 SE 9803959 A SE9803959 A SE 9803959A SE 9803959 A SE9803959 A SE 9803959A SE 9803959 D0 SE9803959 D0 SE 9803959D0
Authority
SE
Sweden
Prior art keywords
trap
activated
papain
cleaving
osteoporosis
Prior art date
Application number
SE9803959A
Other languages
Swedish (sv)
Inventor
Goeran Andersson
Barbro Ek-Rylander
Cornelia Oellig
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to SE9803959A priority Critical patent/SE9803959D0/en
Publication of SE9803959D0 publication Critical patent/SE9803959D0/en
Priority to AU19019/00A priority patent/AU759597B2/en
Priority to EP99962612A priority patent/EP1131463A1/en
Priority to JP2000584097A priority patent/JP2002530117A/en
Priority to PCT/SE1999/002096 priority patent/WO2000031289A1/en
Priority to CA002351872A priority patent/CA2351872A1/en
Priority to NZ511428A priority patent/NZ511428A/en
Priority to IL14288099A priority patent/IL142880A0/en
Priority to US09/442,816 priority patent/US6451548B1/en
Priority to NO20012453A priority patent/NO20012453L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to the use of activated TRAP (tartrate-resistant and purple acid phosphatases) for screening for specific inhibitor of TRAP activity useful in the treatment of diseases or degenerative conditions resulting in increased bone resorption, such as tissue damages, bone metabolic disorders, osteoporosis. TRAP can be activated by proteolytic activation of TRAP e.g. by cleaving with a protease, papain-like enzyme.
SE9803959A 1998-11-19 1998-11-19 inhibitors SE9803959D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE9803959A SE9803959D0 (en) 1998-11-19 1998-11-19 inhibitors
AU19019/00A AU759597B2 (en) 1998-11-19 1999-11-16 Use of activated trap for screening for specific inhibitor of trap and method for aiding in the identification of compound for use in the treatment of diseases or degenerative conditions resulting in increased bone resorption
EP99962612A EP1131463A1 (en) 1998-11-19 1999-11-16 Use of activated trap for screening for specific inhibitor of trap and method for aiding in the identification of a compound for use in the treatment of diseases or degenerative conditions resulting in increased bone resorption
JP2000584097A JP2002530117A (en) 1998-11-19 1999-11-16 Use of Activated TRAP for Screening for Specific Inhibitors of TRAP and Auxiliary Methods of Identifying Compounds for the Treatment of Diseases or Degenerative Conditions that Cause Increased Bone Resorption
PCT/SE1999/002096 WO2000031289A1 (en) 1998-11-19 1999-11-16 Use of activated trap for screening for specific inhibitor of trap and method for aiding in the identification of a compound for use in the treatment of diseases or degenerative conditions resulting in increased bone resorption
CA002351872A CA2351872A1 (en) 1998-11-19 1999-11-16 Use of activated trap for screening for specific inhibitor of trap and method for aiding in the identification of a compound for use in the treatment of diseases or degenerative conditions resulting in increased bone resorption
NZ511428A NZ511428A (en) 1998-11-19 1999-11-16 Use of activated trap for screening for specific inhibitor of trap and method for aiding in the identification of a compound for use in the treatment of diseases or degenerative conditions resulting in increased bone resorption
IL14288099A IL142880A0 (en) 1998-11-19 1999-11-16 Use of activated trap for screening for specific inhibitor of trap and method for aiding in the identification of a compound for use in the treatment of diseases or degenerative conditions resulting in increasing bone resorption
US09/442,816 US6451548B1 (en) 1998-11-19 1999-11-18 Methods for screening for specific inhibitors of trap and identifying compounds for treatment of diseases or conditions resulting in increased bone resorption using activated TRAP
NO20012453A NO20012453L (en) 1998-11-19 2001-05-18 Use of Activated TRAP in Selection of Specific Inhibitors of TRAP, and its Use in Selection of Medicines for Increased Bone Resorption

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9803959A SE9803959D0 (en) 1998-11-19 1998-11-19 inhibitors

Publications (1)

Publication Number Publication Date
SE9803959D0 true SE9803959D0 (en) 1998-11-19

Family

ID=20413342

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9803959A SE9803959D0 (en) 1998-11-19 1998-11-19 inhibitors

Country Status (9)

Country Link
EP (1) EP1131463A1 (en)
JP (1) JP2002530117A (en)
AU (1) AU759597B2 (en)
CA (1) CA2351872A1 (en)
IL (1) IL142880A0 (en)
NO (1) NO20012453L (en)
NZ (1) NZ511428A (en)
SE (1) SE9803959D0 (en)
WO (1) WO2000031289A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002221841A1 (en) * 2000-11-14 2002-05-27 Bayer Aktiengesellschaft Polynucleotide and polypeptide sequences of human purple acid phosphate
WO2002055710A2 (en) * 2001-01-11 2002-07-18 Bayer Ag Regulation of human purple acid phosphatase

Also Published As

Publication number Publication date
WO2000031289A1 (en) 2000-06-02
NO20012453D0 (en) 2001-05-18
NO20012453L (en) 2001-07-19
NZ511428A (en) 2003-06-30
AU1901900A (en) 2000-06-13
CA2351872A1 (en) 2000-06-02
AU759597B2 (en) 2003-04-17
JP2002530117A (en) 2002-09-17
IL142880A0 (en) 2002-03-10
EP1131463A1 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
Amour et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3
Kostoulas et al. Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases
Tortorella et al. ADAMTS-4 (aggrecanase-1): N-terminal activation mechanisms
DK0939628T3 (en) Thiolsulfon-metalloprotease inhibitors
SG166001A1 (en) Methods of generating and screening for proteases with altered specificity
BRPI9909660B8 (en) caspase inhibitor compounds, pharmaceutical composition and use of said compounds
DK0728144T3 (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
BR0210644A (en) Compound, pharmaceutical formulation, method for inhibiting a proline / alanine cleaving protease, method for treatment or prophylaxis of disorders, and use of the compound
PL331598A1 (en) Derivatives of hydroxamic and carboxylic acids of mmp activity and tnf inhibiting action
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
DK0871454T3 (en) Phosphorus-containing inhibitors of cysteine and serine protease
DE69832268D1 (en) Peptidyl-2-amino-1hydroxyalkansulfonsäuren als cystein-protease-inhibitoren
BR0310003A (en) peptide compounds and their use as protease substrates
NO20003828L (en) 2,3,4,5-tetrahydro-1H- [1,4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
NZ513923A (en) Methods for detecting membrane derived caspase activity and modulators thereof
ATE353667T1 (en) USE OF PROTEASOME INHIBITORS TO TREAT DRY EYE
SE9803959D0 (en) inhibitors
DE60044584D1 (en) PROTEASE FROM LUCILIA SERICATA AND ITS USE IN WOUND HEALING
Petrovan et al. Purification and characterization of multisquamase, the prothrombin activator present in Echis multisquamatus venom
BR0213961A (en) Phosphonic Acid Compounds as Serine Protease Inhibitors
BR0316506A (en) Midas and heteroarylsulfonylmethyl hydroxamic acids and their application as protease inhibitors
DK1068533T3 (en) Method for measuring the degree of bone resorption
Pinyachat et al. Albocollagenase, a novel recombinant P-III snake venom metalloproteinase from green pit viper (Cryptelytrops albolabris), digests collagen and inhibits platelet aggregation
SE0102298D0 (en) Crystal structure of enzyme and uses thereof
DE60141573D1 (en) METHOD FOR IDENTIFYING ACTIVITY PROTEASINACTIVATORS